Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"6-hydroxy–1,6–dihydropurine nucleoside" is a synthetic purine nucleoside analog and a small molecule that acts as a potent inhibitor of adenosine deaminase (ADA), an enzyme critical in purine metabolism. It functions as a transition-state or reaction coordinate analogue for ADA and binds tightly to the enzyme's active site via multiple hydrogen bonds. This compound has been used experimentally to study ADA structure and function but is not approved for clinical use or marketed as a pharmaceutical product. Its primary utility is in biochemical research related to ADA inhibition[1][8][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-hydroxy-1,6-dihydro purine nucleoside.